NCT05493566View on ClinicalTrials.gov

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

January 7, 2026

Study Completion Date

January 7, 2027

Conditions
Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC V8Stage IVA Lung Cancer AJCC V8Stage IVB Lung Cancer AJCC V8
Interventions
BIOLOGICAL

Aldesleukin

Given SC

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

30322

RECRUITING

Emory University/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER